OBJECTIVES: This study characterizes the changes in the pharmacokinetics of phenobarbital associated with extracorporeal membrane oxygenation treatment in neonates, to illustrate our findings and provide guidance on dosing. DESIGN: Retrospective pilot population pharmacokinetic analysis. SETTING: Neonatal ICU. PATIENTS: Thirteen critically ill neonates (birth body weight, 3.21 kg [2.65-3.72 kg]; postnatal age at start of treatment: 2 d [0-7 d]; gestational age: 38 wk [38-41 wk]) receiving venovenous or venoarterial extracorporeal membrane oxygenation. INTERVENTIONS: Phenobarbital administered in a loading dose of 7.5 mg/kg (8.5-16 mg/kg) and maintenance dose of 6.9 mg/kg/d (4.5-8.5 mg/kg/d). MEASUREMENTS AND MAIN RESULTS: Therapeutic drug monitoring data were available, yielding 5, 31, and 19 phenobarbital concentrations before, during, and after extracorporeal membrane oxygenation, respectively. Population pharmacokinetic analysis was performed using NONMEM 7.3.0 (ICON Development Solutions, Ellicott City, MD). Maturation functions for clearance and volume of distribution were obtained from literature. In a one-compartment model, clearance and volume of distribution for a typical neonate off extracorporeal membrane oxygenation and with a median birth body weight (3.21 kg) at median postnatal age (2 d) were 0.0096 L/hr (relative SE = 11%)) and 2.72 L (16%), respectively. During extracorporeal membrane oxygenation, clearance was found to linearly increase with time. Upon decannulation, phenobarbital clearance initially decreased and subsequently increased slowly driven by maturation. Extracorporeal membrane oxygenation-related changes in volume of distribution could not be identified, possibly due to sparse data collection shortly after extracorporeal membrane oxygenation start. According to the model, target attainment is achieved in the first 12 days of extracorporeal membrane oxygenation with a regimen of a loading dose of 20 mg/kg and a maintenance dose of 4 mg/kg/d divided in two doses with an increase of 0.25 mg/kg every 12 hours during extracorporeal membrane oxygenation treatment. CONCLUSIONS: We found a time-dependent increase in phenobarbital clearance during the first 12 days of extracorporeal membrane oxygenation treatment in neonates, which results in continuously decreasing phenobarbital exposure and increases the risk of therapeutic failure over time. Due to high unexplained variability, frequent and repeated therapeutic drug monitoring should be considered even with the model-derived regimen.

Department of Clinical Pharmacy St Antonius Hospital Nieuwegein The Netherlands

Department of Pediatrics 1st Faculty of Medicine and General University Hospital Charles University Prague Czech Republic

Division of Systems Biomedicine and Pharmacology Leiden Academic Centre for Drug Research Leiden University Leiden The Netherlands

Institute of Pharmacology 1st Faculty of Medicine and General University Hospital Charles University Prague Czech Republic

Intensive Care and Department of Pediatric Surgery Erasmus MC Sophia Children's Hospital Rotterdam The Netherlands

See more in PubMed

Wildschut ED, Ahsman MJ, Houmes RJ, et al. Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation (ECMO). Curr Drug Metab 2012; 13:767–777

Lorusso R, Alexander P, Rycus P, et al. The Extracorporeal Life Support Organization Registry: Update and perspectives. Ann Cardiothorac Surg 2019; 8:93–98

Wildschut ED, van Saet A, Pokorna P, et al. The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children. Pediatr Clin North Am 2012; 59:1183–1204

Wildschut ED, Ahsman MJ, Allegaert K, et al. Determinants of drug absorption in different ECMO circuits. Intensive Care Med 2010; 36:2109–2116

Ha MA, Sieg AC. Evaluation of altered drug pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation. Pharmacotherapy 2017; 37:221–235

Shekar K, Fraser JF, Smith MT, et al. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care 2012; 27:741.e9–e18

Cheng V, Abdul-Aziz MH, Roberts JA, et al. Optimising drug dosing in patients receiving extracorporeal membrane oxygenation. J Thorac Dis 2018; 10:S629–S641

Italiano D, Capuano A, Alibrandi A, et al. Indications of newer and older anti-epileptic drug use: Findings from a southern Italian general practice setting from 2005-2011. Br J Clin Pharmacol 2015; 79:1010–1019

Šíma M, Pokorná P, Hartinger J, et al. Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia. J Clin Pharm Ther 2018; 43:196–201

Šíma M, Pokorná P, Hronová K, et al. Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. Physiol Res 2015; 64:S513–S519

Fischer JH, Lockman LA, Zaske D, et al. Phenobarbital maintenance dose requirements in treating neonatal seizures. Neurology 1981; 31:1042–1044

Jolley ME, Stroupe SD, Schwenzer KS, et al. Fluorescence polarization immunoassay. iii. An automated system for therapeutic drug determination. Clin Chem 1981; 27:1575–1579

Lindbom L, Pihlgren P, Jonsson EN, et al. PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79:241–257

Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)–a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75:85–94

Keizer RJ, van Benten M, Beijnen JH, et al. Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 2011; 101:72–79

Völler S, Flint RB, Stolk LM, et al.; DINO study group: Model-based clinical dose optimization for phenobarbital in neonates: An illustration of the importance of data sharing and external validation. Eur J Pharm Sci 2017; 109S:S90–S97

Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R. Comput Methods Programs Biomed 2008; 90:154–166

Formulary DNCs. 2019. Available at: https://www.kinderformularium.nl/. Accessed April 19, 2020

De Cock RF, Piana C, Krekels EH, et al. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 2011; 67(Suppl 1):5–16

Shekar K, Roberts JA, Mcdonald CI, et al. Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: Results from an ex vivo study. Crit Care 2015; 19:164

Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res 2018; 46:D1074–D1082

Dagan O, Klein J, Gruenwald C, et al. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 1993; 15:263–266

Kleiber N, Mathôt RAA, Ahsman MJ, et al. Population pharmacokinetics of intravenous clonidine for sedation during paediatric extracorporeal membrane oxygenation and continuous venovenous hemofiltration. Br J Clin Pharmacol 2017; 83:1227–1239

Di Nardo M, Wildschut ED. Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics. J Thorac Dis 2018; 10:S642–S652

Meropenem Disposition in Neonatal and Pediatric Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy

What is the Best Predictor of Phenobarbital Pharmacokinetics to Use for Initial Dosing in Neonates?